以Pembrolizumab和Lenvatinib治療晚期子宮內膜癌

Pembrolizumab and lenvatinib in women with advanced endometrial cancer

合併paclitaxel和carboplatin是治療復發性或晚期子宮內膜癌的第一線藥物，但治療無效時，可能要考慮使用免疫治療或靶標治療。Pembrolizumab是一抗程序性細胞死亡的單株抗體，對具MSI-H (microsatellite instability-high)或dMMR (mismatch repair-deficient)的晚期子宮內膜癌，其治療效果不錯。而lenvatinib是一強的血管抑制劑，如合併pembrolizumab和lenvatinib來治療復發性或晚期子宮內膜癌，研究報告的效果是良好的，最近，FDA亦通過合併使用免疫治劑pembrolizumab和血管抑制劑lenvatinib，來治療非MSI-H和dMMR的晚期子宮內膜癌患者。

Standard first-line treatment for women with recurrent or advanced endometrial cancer is using with paclitaxel and carboplatin. However, for those patients whose disease do not respond, immunotherapy or molecular-targeted agents should be considerated for anticancer drugs. Pembrolizumab is an antiprogtammed death 1 monoclonal antibody, and it had compelling antitumor activity in advanced endometrial cancer with microsatellite instability- high (MSI-H) or mismatch repair-deficient (dMMR). Lenvatinib is a potent angio-genesis inhibitor. The combination of pembrolizumab and lenvatinib has emerged as an effective treatment for recurrent or advanced endometrial cancer. Recently, FDA approved the combination of pembrolizumab with multikinase inhibitor lenvatinib for the treatment with advanced endometrial cancer that is not MSI-H or dMMR.